Key facts
- MiCan Technologies’s last known valuation is $14.1M (Jan 2025).
- It has raised $7.5M; the latest was Later Stage VC ($1.8M) in Jan 2025.
- Notable investors include Japan External Trade Organization, Globis Capital Partners, UntroD, FASTAR, Osaka University Venture Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for MiCan Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for MiCan Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MiCan Technologies
Developer of regenerative medicine-based monocytic cell lines and evaluation systems designed to improve the accuracy and reliability of safety testing, infectious disease research, and pharmaceutical evaluation. The company's systems offer proprietary immortalized monocyte cells, gene editing and differentiation technologies, integrated production processes, and evaluation kits, enabling pharmaceutical companies, biotechnology firms, and research institutions to conduct reproducible, virus-free testing and consistent drug and material assessments.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2016
- Employees
- 20
- Website
- micantechnologies.com/
- Ownership
- Privately Held (backing)
MiCan Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MiCan Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MiCan Technologies in its N-PORT filings yet. We sweep new filings monthly.